肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

淋巴瘤中西医结合诊疗专家共识(2020年)

2021-09-20 中国中西医结合学会血液学专业委员会淋巴瘤专家委员会 中国中西医结合杂志

淋巴瘤

淋巴瘤（lymphoma）是我国多发恶性肿瘤之一。

中文标题：

淋巴瘤中西医结合诊疗专家共识(2020年)

发布机构：

中国中西医结合学会血液学专业委员会淋巴瘤专家委员会

发布日期：

2021-09-20

简要介绍：

淋巴瘤（lymphoma）是我国多发恶性肿瘤之一,2019年发布的我国淋巴瘤的确诊发病率为7.04/10万,死亡率为3.62/10万[1]。淋巴瘤病理类型复杂,可分为霍奇金（Hodgkin lymphoma,HL）和非霍奇金淋巴瘤（non-Hodgkin lymphoma,NHL） [2],治疗原则各不相同。2009年《规范常见血液病中医病名建议》中确定"恶核"为淋巴瘤中医学病名[3],本病以"痰"为根本病理因素,合并"寒""虚""瘀""毒"而表现出不同的病机及临床证候。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=淋巴瘤中西医结合诊疗专家共识(2020年).pdf)] GetToolGuiderByIdResponse(projectId=1, id=a88431c00229a9bb, title=淋巴瘤中西医结合诊疗专家共识(2020年), enTitle=, guiderFrom=中国中西医结合杂志, authorId=0, author=, summary=淋巴瘤（lymphoma）是我国多发恶性肿瘤之一。, cover=https://img.medsci.cn/20211218/1639837269737_5579292.jpg, journalId=0, articlesId=null, associationId=2233, associationName=中国中西医结合学会血液学专业委员会淋巴瘤专家委员会, associationIntro=中国中西医结合学会血液学专业委员会淋巴瘤专家委员会, copyright=0, guiderPublishedTime=Mon Sep 20 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">淋巴瘤（lymphoma）是我国多发恶性肿瘤之一,2019年发布的我国淋巴瘤的确诊发病率为7.04/10万,死亡率为3.62/10万</span><sup style="color: #333333;">[1]</sup><span style="color: #333333;">。淋巴瘤病理类型复杂,可分为霍奇金（Hodgkin lymphoma,HL）和非霍奇金淋巴瘤（non-Hodgkin lymphoma,NHL）&nbsp;</span><sup style="color: #333333;">[2]</sup><span style="color: #333333;">,治疗原则各不相同。2009年《规范常见血液病中医病名建议》中确定"恶核"为淋巴瘤中医学病名</span><sup style="color: #333333;">[3]</sup><span style="color: #333333;">,本病以"痰"为根本病理因素,合并"寒""虚""瘀""毒"而表现出不同的病机及临床证候。&nbsp;</span></p>, tagList=[TagDto(tagId=412, tagName=淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=412, guiderKeyword=淋巴瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2848, appHits=103, showAppHits=0, pcHits=601, showPcHits=2745, likes=0, shares=18, comments=4, approvalStatus=1, publishedTime=Sat Dec 18 22:18:35 CST 2021, publishedTimeString=2021-09-20, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Sat Dec 18 22:26:08 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Fri Jan 05 17:36:03 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=淋巴瘤中西医结合诊疗专家共识(2020年).pdf)])
淋巴瘤中西医结合诊疗专家共识(2020年).pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1225887, encodeId=56a6122588e8c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbb55483145, createdName=charly, createdTime=Sat Jun 11 21:47:58 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207083, encodeId=e50e120e083f6, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:41:31 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186325, encodeId=eab8118632582, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Thu Jan 20 09:01:24 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183091, encodeId=397e1183091a6, content=不错！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f11470307, createdName=仙境海岸, createdTime=Tue Jan 11 09:03:38 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-06-11 charly

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1225887, encodeId=56a6122588e8c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbb55483145, createdName=charly, createdTime=Sat Jun 11 21:47:58 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207083, encodeId=e50e120e083f6, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:41:31 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186325, encodeId=eab8118632582, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Thu Jan 20 09:01:24 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183091, encodeId=397e1183091a6, content=不错！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f11470307, createdName=仙境海岸, createdTime=Tue Jan 11 09:03:38 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-03-30 56446_2968

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1225887, encodeId=56a6122588e8c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbb55483145, createdName=charly, createdTime=Sat Jun 11 21:47:58 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207083, encodeId=e50e120e083f6, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:41:31 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186325, encodeId=eab8118632582, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Thu Jan 20 09:01:24 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183091, encodeId=397e1183091a6, content=不错！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f11470307, createdName=仙境海岸, createdTime=Tue Jan 11 09:03:38 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-01-20 gujie_happy

    学习！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1225887, encodeId=56a6122588e8c, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dbb55483145, createdName=charly, createdTime=Sat Jun 11 21:47:58 CST 2022, time=2022-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207083, encodeId=e50e120e083f6, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:41:31 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186325, encodeId=eab8118632582, content=学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Thu Jan 20 09:01:24 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183091, encodeId=397e1183091a6, content=不错！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5f11470307, createdName=仙境海岸, createdTime=Tue Jan 11 09:03:38 CST 2022, time=2022-01-11, status=1, ipAttribution=)]
    2022-01-11 仙境海岸

    不错！

    0

相关指南

2021 BSH指南：成熟T细胞和自然杀伤细胞淋巴瘤（不包括皮肤T细胞淋巴瘤）的管理

英国血液病学学会(BSH,British Society for Haematology) · 2021-11-22

中国Castleman病诊断与治疗专家共识

中国抗癌协会血液肿瘤专业委员会 · 2021-07-14

中国淋巴瘤治疗指南(2021年版)

中国抗癌协会淋巴瘤专业委员会 · 2021-07-03

澳大利亚和新西兰关于 COVID-19 大流行期间淋巴瘤、慢性淋巴细胞白血病和骨髓瘤管理的共识声明 2020

暂未更新 · 2020-07-15

2021 共识建议：玻璃体视网膜淋巴瘤的诊断

国外肿瘤科相关专家小组（统称） · 2021-05-19

淋巴瘤 18F-FDG PET/CT及PET/MR显像临床应用指南（2021版）

中华医学会核医学分会(CSNM,Chinese Society of Nuclear Medicine) · 2021-03-28

拓展阅读

2010 ACR 霍奇金淋巴瘤临床I期和II期的放疗

美国放射学会(ACR,American College of Radiology) · 2010-01-01

2010 BCSH 淋巴瘤诊断报告最佳实践指南

英国血液学标准委员会(BCSH,British Committee for Standards in Haematology) · 2010-04-01

ESMO临床诊疗指南：弥漫大B细胞非霍奇金淋巴瘤（2010）

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-21

2011 ESMO临床诊疗指南：新诊断和复发性滤泡性淋巴瘤的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2011-01-01

2011 ESMO霍奇金淋巴瘤临床诊疗指南

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2011-01-01

2011 中国儿童非霍奇金淋巴瘤诊疗建议

中华医学会儿科学分会血液学组 · 2011-03-01